A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of KM-023 After Oral Administration in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2012
At a glance
- Drugs KM 023 (Primary)
- Indications HIV infections; Viral infections
- Focus Adverse reactions
- 25 Jul 2012 Actual end date (1 Mar 2012) added as reported by ClinicalTrials.gov.
- 31 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.